The heterocyclic
amine 2-amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine (
PhIP) targets multiple organs for
tumorigenesis in the rat, including the colon and the skin.
PhIP-induced skin
tumors were subjected to mutation screening, which identified genetic changes in Hras (7/40, 17.5%) and Tp53 (2/40, 5%), but not in Ctnnb1, a commonly mutated gene in
PhIP-induced colon
tumors. Despite the absence of Ctnnb1 mutations, β-
catenin was overexpressed in nuclear and plasma membrane fractions from
PhIP-induced skin
tumors, coinciding with loss of
p120-catenin from the plasma membrane, and the appearance of multiple p120-catenin-associated bands in the nuclear extracts. Real-time RT-PCR revealed that
p120-catenin isoforms 1 and 4 were upregulated in
PhIP-induced skin
tumors, whereas
p120-catenin isoform 3 was expressed uniformly, compared with adjacent normal-looking tissue. In human
epidermoid carcinoma and
colon cancer cells, transient transfection of
p120-catenin isoform 1A enhanced the viability and cell invasion index, whereas transient transfection of
p120-catenin isoform 4A increased cell viability and cell proliferation. Knockdown of
p120-catenin revealed a corresponding reduction in the expression of β-
catenin and a transcriptionally regulated target, Ccnd1/
Cyclin D1. Co-immunoprecipitation experiments identified associations of β-
catenin with
p120-catenin isoforms in
PhIP-induced skin
tumors and human
cancer cell lines. The results are discussed in the context of therapeutic strategies that might target different
p120-catenin isoforms, providing an avenue to circumvent constitutively active β-
catenin arising via distinct mechanisms in skin and
colon cancer.